The Abu Dhabi Department of Health has authorized Medicus Pharma’s PRECISION-E2 Phase 2a study of Teverelix in women with moderate-to-severe symptomatic endometriosis. The randomized, placebo-controlled study will enroll approximately 84 participants and examine whether different injectable Teverelix regimens can maintain estradiol within a predefined therapeutic range while integrating hormonal, clinical and genomic data. Authorization allows the program to advance toward patient enrollment, but site-level ethics and Institutional Review Board approvals are still required, and the decision does not establish that Teverelix is safe or effective for endometriosis.
The trial is unusual because it will prospectively explore whether genetic variation helps explain differences in hormone suppression, pain improvement and treatment tolerability. Those analyses are exploratory, and any proposed genetic response signature would require confirmation in later studies before it could be used to select patients or guide prescribing.
Four treatment groups will test Teverelix dose, injection route and estradiol control
PRECISION-E2 will randomize participants equally among four groups: 60 mg Teverelix administered subcutaneously, 90 mg administered subcutaneously, 90 mg administered intramuscularly and subcutaneous placebo. The study will be conducted at multiple investigational sites in the United Arab Emirates.
The primary endpoint is the proportion of participants who achieve and maintain serum estradiol between approximately 20 and 50 picograms per milliliter for at least 14 consecutive days after treatment. Medicus refers to this range as the Barbieri therapeutic window, a level intended to suppress estrogen-dependent disease activity without producing the full hormonal deprivation associated with more severe hypoestrogenic effects.
This endpoint makes PRECISION-E2 primarily a pharmacodynamic and dose-selection study. It is designed to determine how reliably the drug controls estradiol and whether the subcutaneous or intramuscular route provides the more useful exposure profile. The trial is not primarily powered to demonstrate a definitive reduction in endometriosis pain or establish superiority over an approved therapy.
Secondary and exploratory measures include Teverelix blood concentrations, luteinizing hormone and follicle-stimulating hormone levels, bone-turnover biomarkers, immunogenicity, safety, endometriosis-associated pain and quality-of-life assessments. These outcomes should indicate whether hormonal suppression is accompanied by early clinical improvement, but the approximately 84-patient size limits the strength of efficacy conclusions that can be drawn from subgroup or genomic analyses.
The inclusion of three active regimens may help identify whether increasing the dose from 60 mg to 90 mg produces more consistent estradiol control and whether intramuscular administration extends exposure differently from subcutaneous delivery. The study will also need to establish whether any stronger hormonal effect is accompanied by more hot flashes, menstrual changes, mood symptoms or other effects associated with reduced estrogen.
Genomic profiling may identify response patterns but will not create a validated test
PRECISION-E2 plans to combine treatment outcomes with genomic information from participating women, subject to applicable consent, privacy and governance requirements. The program may draw on infrastructure associated with the Emirati Genome Program, Malaffi health-information network and a controlled Trusted Research Environment.
Investigators will examine predefined genes and biological pathways involving estrogen receptors, estrogen production and metabolism, gonadotropin signaling, inflammation and pain perception. Candidate genes identified by Medicus include ESR1, ESR2, CYP19A1, GNRHR, FSHR and LHCGR.
The scientific objective is to determine whether genetic differences are associated with Teverelix exposure, depth or duration of estradiol suppression, pain outcomes or adverse effects. For example, variation affecting estrogen-receptor signaling or the GnRH receptor could theoretically influence how strongly a patient responds to hormonal intervention.
The study cannot establish a clinically validated genomic predictor by itself. With approximately 84 participants divided among four groups, the number of patients carrying any particular genetic variant may be small. Testing numerous genes and outcomes also increases the likelihood of associations appearing by chance unless the analyses are carefully predefined and later reproduced. Medicus has acknowledged that any candidate biomarker or multi-gene signature would need confirmation in subsequent clinical trials.
A promising association could nevertheless influence future development. Medicus could use the findings to enrich a Phase 2b or pivotal study for patients considered more likely to achieve controlled hormone suppression or clinical improvement. The data could also help the company avoid a one-dose-fits-all strategy by supporting treatment selection based on pharmacology, clinical characteristics or eventually validated biomarkers.
Genomic findings should not be interpreted as evidence that endometriosis is caused by one gene or can be managed through a simple genetic test. Endometriosis is biologically heterogeneous, and treatment response can be influenced by disease location, lesion burden, hormonal history, pain sensitization, inflammation and prior surgery or medication, in addition to inherited variation.
Earlier Phase 1 results showed hormone suppression but did not test women with endometriosis
The clinical basis for PRECISION-E2 includes two randomized, placebo-controlled Phase 1 studies involving 48 healthy premenopausal women. Participants received single subcutaneous doses of Teverelix so investigators could evaluate pharmacokinetics, reproductive-hormone suppression, bone-turnover markers and short-term safety.
Medicus reported that luteinizing hormone and follicle-stimulating hormone declined within 24 hours. Estradiol suppression was dose dependent and reversible, while higher doses produced pharmacodynamic effects lasting approximately two to three weeks after one injection. Several participants reached estradiol levels within the range considered potentially relevant for endometriosis treatment.
No drug-related serious adverse events were reported, and treatment-emergent events were described as mild to moderate. Bone-turnover biomarkers remained stable during the short observation period. These results support further testing but cannot establish long-term bone safety because the participants received only a single dose and were not exposed for the months or years that chronic endometriosis management may require.
Healthy-volunteer hormone data also do not prove clinical efficacy in endometriosis. PRECISION-E2 must determine whether the formulation produces predictable suppression in patients with active symptoms and whether hormonal changes correspond with reductions in pelvic pain, menstrual pain and disruption of daily activities.
Teverelix is formulated as a microcrystalline depot and directly antagonizes the GnRH receptor. Unlike GnRH agonists, which initially stimulate reproductive hormones before suppressing them, an antagonist is intended to reduce luteinizing hormone, follicle-stimulating hormone and downstream sex hormones without an initial flare.
Medicus is attempting to differentiate Teverelix from daily oral GnRH antagonists through sustained injectable exposure. Less frequent dosing could reduce the burden of taking a tablet every day, but an injection may be less convenient for some patients and could make dose reversal slower if adverse effects occur. The actual dosing interval for endometriosis has not yet been established by PRECISION-E2.
Controlled estrogen suppression must balance symptom relief against hypoestrogenic risks
Endometriosis involves tissue resembling the uterine lining growing outside the uterus and is associated with chronic pelvic pain, painful menstruation, pain during sex and infertility. The World Health Organization estimates that it affects approximately 10% of women of reproductive age worldwide, or about 190 million people.
Hormonal treatments aim to reduce stimulation of estrogen-dependent lesions and control symptoms. Suppressing estrogen too deeply or for too long can produce hot flashes and other menopausal symptoms while contributing to loss of bone mineral density. FDA-approved GnRH-antagonist regimens therefore carry warnings and treatment-duration considerations related to bone loss and other hypoestrogenic effects.
PRECISION-E2’s central clinical concept is to find a level of suppression that is strong enough to influence endometriosis while preserving enough estrogen to reduce unwanted effects. Bone-turnover biomarkers may provide an early safety signal, but they are not equivalent to direct measurements of bone mineral density or long-term fracture risk.
The trial will also need to examine variability over time. A participant may initially enter the target estradiol window but leave it before 14 days, remain below the desired range for too long or experience hormone rebound before the next planned injection. Average hormone concentrations may therefore be less informative than the proportion of patients achieving sustained, controlled suppression.
Pain outcomes require careful interpretation because endometriosis symptoms fluctuate with the menstrual cycle and are influenced by previous treatments, analgesic use and individual pain processing. A placebo-controlled design should improve reliability, but the exploratory status and limited study size mean that any clinical-activity signal will need confirmation in a larger and longer trial.
The Department of Health authorization moves Teverelix into patient testing for endometriosis and provides Medicus with an opportunity to compare dose, route and genomic response within one study. The program’s first clinical objective is narrower than demonstrating that the therapy treats the disease. PRECISION-E2 must first show that Teverelix can produce predictable, sustained and tolerable estradiol suppression before the company can justify a larger efficacy trial or a biomarker-guided development strategy.
